Parties d'ouvrages collectifs (3)
  1. 1. Kollmann, T. R., Dauby, N., Harbeson, D. D., Fidanza, M., & Marchant, A. (2021). Host Defense Mechanisms Against Bacteria. In R. Polin, S. Abman, W. Benitz, & D. Rowitch (Eds.), Fetal and Neonatal Physiology. Philadelphia: Elsevier.
  2. 2. Dauby, N., & Marchant, A. (2019). Fetal Infections: Immune Response to Infections during Fetal Life. In Fetal Therapy: Scientific Basis and Critical Appraisal of Clinical Benefits (pp. 215-223). Cambridge University Press. doi:10.1017/9781108564434.022
  3. 3. Cox, A., & Dauby, N. (2014). The challenge of obtaining informed consent in a highly multilingual hospital emergency department. In (Re) visisiting ethics and ideology in situations of conflict. Espagne: Universidad de Alcala - Servicio de Publicationes.
    4.   Articles dans des revues avec comité de lecture (154)
  4. 1. Blumental, S., Lajot, A., Vandromme, M., Lafort, Y., Dockx, Y., Denayer, S., Wampers, A., Nebbioso, A., Tilmanne, A., Mignon, C., Tuerlinckx, D., Rigolle, H., Matthijs, I., Vandersnickt, J., Hellinckx, J., Dewulf, J., Coppens, K., Van Hoorenbeeck, K., Vanlede, K., Winters, L., Seyler, L., Parsy, M.-P., Reynders, M., Balcaen, M., Urbina, M., Dauby, N., Chatzis, O., Naesens, R., Dorval, S., Ternest, S., Vanspeybroeck, S., Goetghebuer, T., Van Ackere, T., Selimaj Kontoni, V., El Bitar, W., Holemans, X., Bruyère, Y., Van Brusselen, D., De Mot, L., & Raes, M. (2026). National real-life impact of prevention with nirsevimab on infants’ RSV hospitalizations in Belgium. BMC infectious diseases. doi:10.1186/s12879-026-13419-y
  5. 2. Spanoghe, M., Molmans, T., Antonacci, T., Burel, E., Herschke, F., Schneider, N., Oustric, P., Thielemans, P., Nicolas, J.-B., Dauby, N., Nicaise, C., Van Weyenbergh, J., & Jamoulle, M. (2026). Commentary: Internal medicine at the crossroads of long COVID diagnosis and management. Frontiers in medicine, 13. doi:10.3389/fmed.2026.1798119
  6. 3. Dauby, N., & Vanbaelen, T. (2026). Screening for Chlamydia trachomatis and Neisseria gonorrhoeae in asymptomatic carriers: now is the time to stop the sexually transmitted exception. CMI Communications, 105186. doi:10.1016/j.cmicom.2026.105186
  7. 4. De Brabandere, L., Herzog, S. A., Desombere, I., Ariën, K. K., Olislagers, V., Georges, D., Dauby, N., Vercoutere, A., Goossens, M. M., Pannus, P., Leuridan, E., Marchant, A., & Maertens, K. (2026). Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness. Vaccine, 73, 128153. doi:10.1016/j.vaccine.2025.128153
  8. 5. Besançon, L., Claude, S., Dauby, N., Kesteman, T., Meyerowitz-Katz, G., & Leyrat, C. (2026). Randomised clinical trials of COVID-19 vaccines are not designed to study non-specific effects on rare mortality. iScience, 114513. doi:10.1016/j.isci.2025.114513
  9. 6. Rousseau, A. F., Dardenne, N., Bertrand, A., Piagnerelli, M., Hoste, E., Grimaldi, D., Michaux, I., De Waele, E., Dumoulin, A., G Jorens, P., van der Hauwaert, E., Vallot, F., Lamote, S., Swinnen, W., De Schryver, N., Fraipont, V., de Mey, N., Dauby, N., Layios, N., Mesland, J. B., Donneau, A.-F., Laterre, P.-F., & Misset, B. (2026). Health-related quality of life trajectories one year after COVID-19–induced ARDS: A secondary analysis of the CONFIDENT trial. Annals of intensive care, 16, 100009. doi:10.1016/j.aicoj.2025.100009
  10. 7. Docquier, L., Taelman, C., Cantinieaux, B., Belhomme, J., de Wind, R., Dauby, N., & Martin, C. (2025). Prevalence of submicroscopic malaria parasitemia among migrant pregnant women: A prospective cohort study. CMI Communications, 2(4), 105131. doi:10.1016/j.cmicom.2025.105131
  11. 8. Cuypers, L., Sanchez, G. J., Herrera Avila, J. P., Naesens, R., Antoine-Moussiaux, T., Herens, S., Holemans, X., Clevenbergh, P. A., Darcis, G., Layeux, B., Buttafuoco, F., Brassinne, L., Paridaens, H., Hites, M., Lagrou, K., Dauby, N., & Desmet, S. (2025). Rapid increase in serotype 4 invasive pneumococcal disease among vulnerable young male adults in Belgium (2020-2024). International journal of infectious diseases, 163, 108216. doi:10.1016/j.ijid.2025.108216
  12. 9. Rose, A. M. C., Nicolay, N., Mazagatos, C., Martínez-Baz, I., Launay, O., De Mot, L., Bella, A., Lazar, M., Machado, A., Kuliešė, M., Abela, S., Vučina, V. V., van Gageldonk-Lafeber, R., Bino, S., Dürrwald, R., Paradowska-Stankiewicz, I., Horváth, J. K., Duffy, R., Husa, P., McMenamin, J., Pozo, F., Howard, J., Latorre-Millán, M., Castilla, J., Nguyen, L. B. L., Dauby, N., Riccardo, F., Ivanciuc, A., Gomez, V., Jančorienė, L., Xuereb, G., Petrović, G., Marbus, S., Vasili, A., Tolksdorf, K., Bogusz, J., Oroszi, B., Domegan, L., Součková, L., Marsh, K., Bacci, S., Kissling, E., & I-MOVE & VEBIS Hospital Network teams, (2025). Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24. BMC medicine, 23(1), 602. doi:10.1186/s12916-025-04426-y
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Suivant >>